IN8bio (INAB) Investor presentation summary

Leadership and expertise

• Leadership team has decades of experience in oncology, cell therapy, business development, and regulatory affairs.

• Team includes founders, scientific, medical, and financial officers with backgrounds in major healthcare and biotech organizations.

Platform and technology

• Focuses on gamma-delta (γδ) T cell therapies and T cell engagers (TCEs) for oncology and autoimmune diseases.

• DeltEx™ platform addresses key biological, clinical, and manufacturing challenges in γδ T cell therapy.

• γδ T cells act as direct killers and orchestrate immune responses, with a favorable safety profile and lower toxicity.

Clinical pipeline and milestones

• Pipeline includes INB-100 (allogeneic γδ T cells for AML), INB-200/400 (drug-resistant immunotherapy for GBM), and INB-619 (γδ TCE for B cell malignancies and autoimmune diseases).

• Multiple near-term readouts expected, including dosing completion, clinical updates, and FDA guidance in 2026.

• $27.1M cash on hand as of Dec 31, 2025, with a cash runway into 2Q27 and no debt.